BASELINE CHARACTERISTICS IN THE "CARDINAL" TRIAL: A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME

被引：0

作者：

Knebelmann, Bertrand ^{[1
]}

Appel, Gerald ^{[2
]}

Block, Geoffrey ^{[3
]}

Chin, Melanie ^{[3
]}

Goldsberry, Angie ^{[3
]}

Inker, Lesley ^{[4
]}

Kashtan, Clifford ^{[5
]}

Meyer, Colin ^{[3
]}

Nozu, Kandai ^{[6
]}

Pergola, Pablo ^{[7
]}

Rastogi, Anjay ^{[8
]}

Rheault, Michelle ^{[5
]}

Silva, Arnold ^{[9
]}

Sprague, Stuart ^{[10
]}

Warady, Bradley ^{[11
]}

Gross, Oliver ^{[12
]}

机构：

[1] Hop Necker Enfants Malad, Paris, France

[2] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA

[3] Reata Pharmaceut Inc, Irving, TX USA

[4] Tufts Univ, Boston, MA 02111 USA

[5] Univ Minnesota, Minneapolis, MN USA

[6] Kobe Univ, Grad Sch Med, Kobe, Hyogo, Japan

[7] Renal Associates, San Antonio, TX USA

[8] Univ Calif Los Angeles, Los Angeles, CA USA

[9] Boise Kidney & Hypertens Inst, Meridian, ID USA

[10] NorthShore Univ HealthSyst, Evanston, IL USA

[11] Univ Missour Kansas City, Sch Med, Kansas City, MO USA

[12] Univ Gottingen, Gottingen, Germany

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2019年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

FP179

引用

页码：104 / 104

页数：1

共 50 条

[21] Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)
Werth, Victoria
Oddis, Chester
Fiorentino, David
Dgetluck, Nancy
Quinn Dinh
Tillinger, Michael
White, Barbara
Lundberg, Ingrid
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[22] Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study
Ikejiri, Kazuaki
Suzuki, Takafumi
Muto, Satsuki
Takama, Hirotaka
Yamawaki, Kengo
Miyazawa, Tatsuya
Urakawa, Itaru
Aoki, Yuichi
Otsuki, Akihito
Katsuoka, Fumiki
Kinoshita, Kengo
Nangaku, Masaomi
Akizawa, Tadao
Yamamoto, Masayuki
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (03) : 225 - 234
[23] Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study
Kazuaki Ikejiri
Takafumi Suzuki
Satsuki Muto
Hirotaka Takama
Kengo Yamawaki
Tatsuya Miyazawa
Itaru Urakawa
Yuichi Aoki
Akihito Otsuki
Fumiki Katsuoka
Kengo Kinoshita
Masaomi Nangaku
Tadao Akizawa
Masayuki Yamamoto
Clinical and Experimental Nephrology, 2024, 28 : 225 - 234
[24] Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial
Heerspink, Hiddo J. Lambers
Chertow, Glenn M.
Akizawa, Tadao
Audhya, Paul
Bakris, George L.
Goldsberry, Angie
Krauth, Melissa
Linde, Peter
McMurray, John J.
Meyer, Colin J.
Parving, Hans-Henrik
Remuzzi, Giuseppe
Christ-Schmidt, Heidi
Toto, Robert D.
Vaziri, Nosratola D.
Wanner, Christoph
Wittes, Janet
Wrolstad, Danielle
de Zeeuw, Dick
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (11) : 2841 - 2850
[25] PHASE 2b/3 TRIAL DESIGN AND BASELINE PATIENT CHARACTERISTICS OF A STUDY TO DETERMINE EFFECTS OF BARDOXOLONE METHYL (BARD) IN PATIENTS WITH TYPE 2 DIABETES (T2DM) AND CHRONIC KIDNEY DISEASE (CKD)
Pergola, P. E.
Grossman, E. B.
Meyer, C.
Richardson, B.
Warnock, D.
AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : A89 - A89
[26] Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Pavel, Marianne
Gross, David J.
Benavent, Marta
Perros, Petros
Srirajaskanthan, Raj
Warner, Richard R. P.
Kulke, Matthew H.
Anthony, Lowell B.
Kunz, Pamela L.
Hoersch, Dieter
Weickert, Martin O.
Lapuerta, Pablo
Jiang, Wenjun
Kassler-Taub, Kenneth
Wason, Suman
Fleming, Rosanna
Fleming, Douglas
Garcia-Carbonero, Rocio
ENDOCRINE-RELATED CANCER, 2018, 25 (03) : 309 - 322
[27] Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Spiera, Robert
Dgetluck, Nancy
Bloom, Bradley
White, Barbara
Denton, Christopher
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[28] PHASE 3 FRACTURE TRIAL OF ODANACATIB FOR OSTEOPOROSIS - BASELINE CHARACTERISTICS AND STUDY DESIGN
Papapoulos, Socrates
Bone, Henry
Dempster, David
Eisman, John
Greenspan, Susan
Mcclung, Michael
Nakamura, Toshitaka
Shih, Joseph
Leung, Albert
Santora, Arthur
Verbruggen, Nadia
Lombardi, Antonio
OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S151 - S151
[29] Phase 3 Fracture Trial Of Odanacatib For Osteoporosis - Baseline Characteristics and Study Design
Papapoulos, Socrates
Bone, Henry G.
Dempster, David W.
Eisman, John
Greenspan, Susan
McClung, Michael
Nakamura, Toshitaka
Shih, Joseph
Leung, Albert
Santora, Arthur
Verbruggen, N.
Lombardi, Antonio
ARTHRITIS AND RHEUMATISM, 2013, 65 : S515 - S516
[30] EMBARK, a Phase 3 Trial Evaluating Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Duchenne Muscular Dystrophy (DMD): Study Design and Baseline Characteristics
Muntoni, Francesco
Mercuri, Eugenio
Schmidt, Ulrike Schara
Komaki, Hirofumi
Richardson, James
Singh, Tejdip
Guridi, Maitea
Mason, Stefanie
Murphy, Alex
Yu, Lixi
Reid, Carol
Darton, Eddie
Wandel, Christoph
Mendell, Jerry
NEUROLOGY, 2023, 100 (17)

← 1 2 3 4 5 →